

REMARKS

The title has been amended to more specifically describe the subject matter to be prosecuted in this application.

Claims 1-25, 28-31, and 34-36 have been canceled without prejudice as directed to non-elected inventions. Applicants reserve the right to prosecute the subject matter of the canceled claims in related applications. Claims 32 and 33 have been amended to delete dependencies upon canceled claims. A copy of the claims as will be pending upon entry of the amendment made herein is attached hereto as Exhibit A.

CONCLUSION

Applicants respectfully request that the above-made amendments and remarks be entered and made of record in the instant application. An early allowance is earnestly requested.

Respectfully submitted,

Date November 28, 2000

Adriane M. Antler 32,605
Adriane M. Antler (Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

003211 0654260

EXHIBIT A

Attorney Docket No. 9632-012
Pending Claims

26. A method for the treatment or prevention of cancer in a subject comprising: administering to the subject an amount of a molecule comprising SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10, which molecule (i) immunospecifically binds CD40,(ii) increases the binding of CD40 ligand to CD40 by at least 45%, and (iii) comprises one or more substitutions or insertions in primary amino acid sequence relative to native monoclonal antibody S2C6 as secreted by the hybridoma deposited with the ATCC and assigned accession number PTA-110, which amount is effective for the treatment or prevention of cancer.
27. A method for the treatment or prevention of cancer in a subject comprising: administering to the subject an amount of a purified protein, which protein (i) competes for binding to CD40 with monoclonal antibody S2C6 as secreted by the hybridoma deposited with the ATCC and assigned accession number PTA-110,(ii) increases the binding of CD40 ligand to CD40 by at least 45%, and (iii) comprises one or more substitutions or insertions in primary amino acid sequence relative to native monoclonal antibody S2C6 as secreted by the hybridoma deposited with the ATCC and assigned accession number PTA-110, which amount is effective for the treatment or prevention of cancer.
32. The method of claim 26 or 27 further comprising administering CD40 ligand to the subject.
33. The method of claim 26 or 27 in which the subject is human.
37. A method for the treatment or prevention of cancer or an immune disorder in a subject comprising administering to the subject, in an amount effective for said treatment or

